HomeCompareDOMIX vs JNJ

DOMIX vs JNJ: Dividend Comparison 2026

DOMIX yields 1.93% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $7.8K in total portfolio value· pulled ahead in Year 7
10 years
DOMIX
DOMIX
● Live price
1.93%
Share price
$11.67
Annual div
$0.23
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.5K
Annual income
$218.49
Full DOMIX calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — DOMIX vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDOMIXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DOMIX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DOMIX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DOMIX
Annual income on $10K today (after 15% tax)
$163.93/yr
After 10yr DRIP, annual income (after tax)
$185.72/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,800.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DOMIX + JNJ for your $10,000?

DOMIX: 50%JNJ: 50%
100% JNJ50/50100% DOMIX
Portfolio after 10yr
$26.4K
Annual income
$2,453.94/yr
Blended yield
9.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DOMIX
No analyst data
Altman Z
549.4
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DOMIX buys
0
JNJ buys
0
No recent congressional trades found for DOMIX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDOMIXJNJ
Forward yield1.93%2.13%
Annual dividend / share$0.23$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$22.5K$30.3K
Annual income after 10y$218.49$4,689.40
Total dividends collected$2.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DOMIX vs JNJ ($10,000, DRIP)

YearDOMIX PortfolioDOMIX Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,893$192.86$10,592$272.30+$301.00DOMIX
2$11,852$196.34$11,289$357.73+$563.00DOMIX
3$12,881$199.65$12,123$472.89+$758.00DOMIX
4$13,985$202.79$13,141$629.86+$844.00DOMIX
5$15,170$205.77$14,408$846.81+$762.00DOMIX
6$16,441$208.60$16,021$1,151.60+$420.00DOMIX
7← crossover$17,803$211.28$18,122$1,588.22$319.00JNJ
8$19,263$213.82$20,930$2,228.20$1.7KJNJ
9$20,827$216.22$24,792$3,191.91$4.0KJNJ
10$22,504$218.49$30,274$4,689.40$7.8KJNJ

DOMIX vs JNJ: Complete Analysis 2026

DOMIXStock

Under normal circumstances, the fund primarily invests in mid- and large- capitalization companies located in Europe, the Asia-Pacific region, and throughout the rest of the world. Its investments will be tied economically to at least 10 different countries other than the U.S. and at least 40% of the fund's assets will be invested in companies tied economically to countries outside the U.S. The adviser seeks to identify investment opportunities for the fund that create positive environmental and social outcomes for people and the planet while seeking competitive financial returns.

Full DOMIX Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DOMIX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DOMIX vs SCHDDOMIX vs JEPIDOMIX vs ODOMIX vs KODOMIX vs MAINDOMIX vs ABBVDOMIX vs MRKDOMIX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.